Biotinylated SARS-CoV-2 Spike RBD Beta Variant

Product Description

Biotinylated SARS-CoV-2 Spike RBD Beta Variant
Catalog number: B2010503
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 25 ug
Molecular Weight or Concentration: 27 kDa
Supplied as: Liquid Solution
Applications: molecular component of many serological and antigenic assays for SARS-CoV-2 and its variants
Storage: -20℃
Keywords: Beta Variant Spike, B.1.351 Spike RBD, Beta RBD, Biotin Beta RBD
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

Download SARS-CoV-2 Brochure

References:
1: Aleem A, Akbar Samad AB, Slenker AK. Emerging Variants of SARS-CoV-2 And
Novel Therapeutics Against Coronavirus (COVID-19). 2021 Jul 18. In: StatPearls
[Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–.

2: Binette V, Côté S, Haddad M, Nguyen PT, Bélanger S, Bourgault S, Ramassamy C,
Gaudreault R, Mousseau N. Corilagin and 1,3,6-Tri-O-galloy-β-D-glucose:
potential inhibitors of SARS-CoV-2 variants. Phys Chem Chem Phys. 2021 Jul
14;23(27):14873-14888.

3: Kim Y, Gaudreault NN, Meekins DA, Perera KD, Bold D, Trujillo JD, Morozov I,
McDowell CD, Chang KO, Richt JA. Effects of Spike Mutations in SARS-CoV-2
Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and
Neutralization. bioRxiv [Preprint]. 2021 Aug 25:2021.08.25.457627.

4: Jin D, Wei J, Sun J. Analysis of the molecular mechanism of SARS-CoV-2
antibodies. Biochem Biophys Res Commun. 2021 Aug 20;566:45-52.

5: Jette CA, Cohen AA, Gnanapragasam PNP, Muecksch F, Lee YE, Huey-Tubman KE,
Schmidt F, Hatziioannou T, Bieniasz PD, Nussenzweig MC, West AP, Keeffe JR,
Bjorkman PJ, Barnes CO. Broad cross-reactivity across sarbecoviruses exhibited
by a subset of COVID-19 donor-derived neutralizing antibodies. bioRxiv
[Preprint]. 2021 Apr 26:2021.04.23.441195.

6: Malladi SK, Patel UR, Rajmani RS, Singh R, Pandey S, Kumar S, Khaleeq S, van
Vuren PJ, Riddell S, Goldie S, Gayathri S, Chakraborty D, Kalita P, Pramanick I,
Agarwal N, Reddy P, Girish N, Upadhyaya A, Khan MS, Kanjo K, Bhat M, Mani S,
Bhattacharyya S, Siddiqui S, Tyagi A, Jha S, Pandey R, Tripathi S, Dutta S,
McAuley AJ, Singanallur NB, Vasan SS, Ringe RP, Varadarajan R. Immunogenicity
and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor
Binding Domain Derivative. ACS Infect Dis. 2021 Aug 13;7(8):2546-2564.

7: Chen L, Zody MC, Di Germanio C, Martinelli R, Mediavilla JR, Cunningham MH,
Composto K, Chow KF, Kordalewska M, Corvelo A, Oschwald DM, Fennessey S,
Zetkulic M, Dar S, Kramer Y, Mathema B, Germer S, Stone M, Simmons G, Busch MP,
Maniatis T, Perlin DS, Kreiswirth BN. Emergence of Multiple SARS-CoV-2 Antibody
Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma
Treatment. mSphere. 2021 Aug 25;6(4):e0048021.

8: Tian F, Tong B, Sun L, Shi S, Zheng B, Wang Z, Dong X, Zheng P. N501Y
mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor
ACE2. Elife. 2021 Aug 20;10:e69091.

9: Makdasi E, Zvi A, Alcalay R, Noy-Porat T, Peretz E, Mechaly A, Levy Y,
Epstein E, Chitlaru T, Tennenhouse A, Aftalion M, Gur D, Paran N, Tamir H,
Zimhony O, Weiss S, Mandelboim M, Mendelson E, Zuckerman N, Nemet I, Kliker L,
Yitzhaki S, Shapira SC, Israely T, Fleishman SJ, Mazor O, Rosenfeld R. The
neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal
antibodies is retained against viral variants. Cell Rep. 2021 Aug 21:109679.
10: Lee YG, Kang KW, Hong W, Kim YH, Oh JT, Park DW, Ko M, Bai YF, Seo YJ, Lee
SM, Kim H, Kang SC. Potent antiviral activity of Agrimonia pilosa, Galla rhois,
and their components against SARS-CoV-2. Bioorg Med Chem. 2021 Sep 1;45:116329.

Products Related to Biotinylated SARS-CoV-2 Spike RBD Beta Variant : SARS-CoV-2